As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009.

Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.

“We are very pleased with this collaboration”, stated Matthieu Frechin, Deputy General Manager of Vétoquinol, “which enables us to introduce an innovative new medication to the U.S. market. The announcement of the FDA’s approval to market Surolan® in the United States has been very well received by the American veterinary profession.”

Surolan® will be launched at the next North American Veterinary Congress in Orlando, Florida, which opens on January 16.

Press release